Predictive Markers of Immune Response in Glioblastoma: Hopes and Facts

References

• Stupp R , MasonWP, van denBent MJet al. Radiotherapy plus concomitant and adjuvant temozolomide for GBM. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R , HegiME, MasonWPet al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in GBM in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.10(5), 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Tosoni A , FranceschiE, PoggiR, BrandesAA. Relapsed GBM: treatment strategies for initial and subsequent recurrences. Curr. Treat. Options Oncol.17(9), 49 (2016).
   PubMed Web of Science ®Google Scholar
• Franceschi E , LambertiG, PaccapeloAet al. Third-line therapy in recurrent GBM: is it another chance for bevacizumab? J. Neurooncol. 139(2), 383–388 (2018).
   PubMed Web of Science ®Google Scholar
• Sharma P , AllisonJP. The future of immune checkpoint therapy. Science348(6230), 56–61 (2015).
   PubMed Web of Science ®Google Scholar
• Omuro A , VlahovicG, LimMet al. Nivolumab with or without ipilimumab in patients with recurrent GBM: results from exploratory Phase I cohorts of CheckMate 143. Neuro. Oncol.20(5), 674–686 (2018).
   PubMed Web of Science ®Google Scholar
• Schalper KA , Rodriguez-RuizME, Diez-ValleRet al. Neoadjuvant nivolumab modifies the tumour immune microenvironment in resectable GBM. Nat. Med.25(3), 470–476 (2019).
   PubMed Web of Science ®Google Scholar
• Reardon DA , OmuroA, BrandesAAet al. Randomized Phase III study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent GBM: checkMate 143. Neuro Oncol.19(3.1), iii21 (2017).
   Google Scholar
• Lukas RV , RodonJ, BeckerKet al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J. Neurooncol.140(2), 317–328 (2018).
   PubMed Web of Science ®Google Scholar
• Anna C Filley , MarioHenriquez, MahuaDey. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget8(53), 91779–91794 (2017).
   PubMedGoogle Scholar
• Janning M , KobusF, BabayanAet al. Determination of PD-L1 expression in circulating tumour cells of NSCLC patients and correlation with response to PD-1/PD-L1 inhibitors. Cancers (Basel)11(6), E835 (2019).
   PubMed Web of Science ®Google Scholar
• Kim KJ , YangHK, KimWH, KangGH. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. Oncotarget8(35), 58887–58902 (2017).
   PubMedGoogle Scholar
• Arora S , VelichinskiiR, LeshRWet al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumours. Adv. Ther.36(10), 2638–2678 (2019).
   PubMed Web of Science ®Google Scholar
• Reck M , Rodríguez-AbreuD, RobinsonAGet al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med.375(19), 1823–1833 (2016).
   PubMed Web of Science ®Google Scholar
• Ozaki Y , MutoS, TakagiHet al. Tumour mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer. Cancer Immunol. Immunother.69(1), 127–134 (2020).
   PubMed Web of Science ®Google Scholar
• Goodman AM , KatoS, BazhenovaLet al. Tumour mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther.16(11), 2598–2608 (2017).
   PubMed Web of Science ®Google Scholar
• Chan TA , YarchoanM, JaffeeEet al. Development of tumour mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol.30(1), 44–56 (2019).
   PubMed Web of Science ®Google Scholar
• Park J , KwonM, KimKHet al. Immune checkpoint inhibitor-induced reinvigoration of tumour-infiltrating CD8(+) T cells is determined by their differentiation status in GBM. Clin Cancer Res.25(8), 2549–2559 (2019).
   PubMed Web of Science ®Google Scholar
• Louveau A , SmirnovI, KeyesTJet al. Structural and functional features of central nervous system lymphatic vessels. Nature523(7560), 337–341 (2015).
   PubMed Web of Science ®Google Scholar
• Aspelund A , AntilaS, ProulxSTet al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med.212(7), 991–999 (2015).
   PubMed Web of Science ®Google Scholar
• De Simone R , GiampaoloA, GiomettoBet al. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J. Neuropathol. Exp. Neurol.54(2), 175–187 (1995).
   PubMed Web of Science ®Google Scholar
• Aloisi F , RiaF, PennaG, AdoriniL. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J. Immunol.160(10), 4671–4680 (1998).
   PubMed Web of Science ®Google Scholar
• Carson MJ , SutcliffeJG, CampbellIL. Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation. J. Neurosci. Res.55(1), 127–134 (1999).
   PubMed Web of Science ®Google Scholar
• Perng P , LimM. Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front. Oncol.5, 153 (2015).
   PubMed Web of Science ®Google Scholar
• Vitkovic L , MaedaS, SternbergE. Anti- inflammatory cytokines: expression and action in the brain. Neuroimmunomodulation9, 295–312 (2001).
   PubMed Web of Science ®Google Scholar
• Gong D , ShiW, YiSJ, ChenH, GroffenJ, HeisterkampN. TGFbeta signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol.13, 31 (2012).
   PubMed Web of Science ®Google Scholar
• Wainwright DA , BalyasnikovaIV, ChangALet al. IDO expression in brain tumours increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res.18, 6110–6121 (2012).
   PubMed Web of Science ®Google Scholar
• Uyttenhove C , PilotteL, ThéateIet al. Evidence for a tumoural immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med.9, 1269–1274 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang I , AlizadehD, LiangJet al. Characterization of arginase expression in glioma-associated microglia and macrophages. PLoS ONE11, e0165118 (2016).
   PubMedGoogle Scholar
• Hawkins RA , O’KaneRL, SimpsonIA, VinaJR. Structure of the blood–brain barrier and its role in the transport of amino acids. J. Nutr.136, S218–S226 (2006).
   PubMed Web of Science ®Google Scholar
• Okada H , WellerM, HuangRet al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol.16(15), e534–e542 (2015).
   PubMedGoogle Scholar
• Shi Y . Regulatory mechanisms of PD-L1 expression in cancer cells. Cancer Immunol. Immunother.67(10), 1481–1489 (2018).
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb (2019). https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-provides-update-phase-3-opdivo-nivolumab-
   Google Scholar
• Bristol-Myers Squibb (2019). https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-phase-3-checkmate-498-study-did
   Google Scholar
• Wei R , GuoL, WangQ, MiaoJ, KwokHF, LinY. Targeting PD-L1 protein: translation, modification and transport. Curr. Protein Pept. Sci.20(1), 82–91 (2019).
   PubMed Web of Science ®Google Scholar
• Patel SP , KurzrockR. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther.14(4), 847–856 (2015).
   PubMed Web of Science ®Google Scholar
• Nduom EK , WeiJ, YaghiNKet al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol.18(2), 195–205 (2016).
   PubMed Web of Science ®Google Scholar
• Chen RQ , LiuF, QiuXY, ChenXQ. The prognostic and therapeutic value of PD-L1 in glioma. Front. Pharmacol.9, 1503 (2019).
   PubMed Web of Science ®Google Scholar
• Garber ST , HashimotoY, WeathersSPet al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol.18, 1357–1366 (2016).
   PubMed Web of Science ®Google Scholar
• Hodges TR , OttM, XiuJet al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol.19, 1047–1057 (2017).
   PubMed Web of Science ®Google Scholar
• Berghoff AS , KieselB, WidhalmGet al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol.19, 1460–1468 (2017).
   PubMed Web of Science ®Google Scholar
• Weller M , ReardonD, BrandesAAet al. Nivolumab vs bevacizumab in patients with recurrent glioblastoma: exploratory analysis of MGMT methylation status and baseline corticosteroid use. Neuro Oncol.21(S6), vi12 (2019).
   Google Scholar
• Hellmann MD , CiuleanuTE, PluzanskiAet al. Nivolumab plus ipilimumab in lung cancer with a high tumour mutational burden. N. Engl. J. Med.378(22), 2093–2104 (2018).
   PubMed Web of Science ®Google Scholar
• Goodman AM , KatoS, BazhenovaLet al. Tumour mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther.16(11), 2598–2608 (2017).
   PubMed Web of Science ®Google Scholar
• Labriola M , ZhuJ, GuptaRet al. Characterization of tumour mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.37(S7), 589–589 (2019).
   PubMedGoogle Scholar
• Zehir A , BenayedR, ShahRHet al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10.000 patients. Nat. Med.23(6), 703–713 (2017).
   PubMed Web of Science ®Google Scholar
• McDonald KA , KawaguchiT, QiQet al. Tumour heterogeneity correlates with less immune response and worse survival in breast cancer patients. Ann. Surg. Oncol.26(7), 2191–2199 (2019).
   PubMed Web of Science ®Google Scholar
• Johanns TM , MillerCA, DorwardIGet al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov.6(11), 1230–1236 (2016).
   PubMed Web of Science ®Google Scholar
• Snyder A , WolchokJD. Successful treatment of a patient with glioblastoma and a germline POLE mutation: where next?Cancer Discov.6(11), 1210–1211 (2016).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC , KimBT. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. J. Neurooncol.133(3), 561–569 (2017).
   PubMed Web of Science ®Google Scholar
• Ranjan S , QuezadoM, GarrenNet al. Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. BMC Cancer18(1), 239 (2018).
   PubMed Web of Science ®Google Scholar
• AlHarbi M , AliMobark N, AlMubarakLet al. Durable response to nivolumab in a pediatric patient with refractory glioblastoma and constitutional biallelic mismatch repair deficiency. Oncologist23(12), 1401–1406 (2018).
   PubMed Web of Science ®Google Scholar
• Kurz SC , CabreraLP, HastieDet al. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology91(14), e1355–e1359 (2018).
   PubMed Web of Science ®Google Scholar
• Draaisma K , WijnengaMM, WeeninkBet al. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathol. Commun.3, 88 (2015).
   PubMed Web of Science ®Google Scholar
• Hodges TR , OttM, XiuJet al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol.19(8), 1047–1057 (2017).
   PubMed Web of Science ®Google Scholar
• Le DT , UramJN, WangHet al. PD-1 blockade in tumours with mismatch-repair deficiency. N. Engl. J. Med.372(26), 2509–2520 (2015).
   PubMed Web of Science ®Google Scholar
• Le DT , DurhamJN, SmithKNet al. Mismatch repair deficiency predicts response of solid tumours to PD-1 blockade. Science357(6349), 409–413 (2017).
   PubMed Web of Science ®Google Scholar
• Marabelle A , LeDT, AsciertoPAet al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J. Clin. Oncol.38(1), 1–10 (2020).
   PubMed Web of Science ®Google Scholar
• Gorlia T , StuppR, BrandesAAet al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group Phase I and II clinical trials. Eur. J. Cancer48(8), 1176–1184 (2012).
   PubMed Web of Science ®Google Scholar
• Franceschi E , TosoniA, MinichilloSet al. PERNO study group. the prognostic roles of gender and O6-Methylguanine-DNA methyltransferase methylation status in glioblastoma patients: the female power. World Neurosurg.112, e342–e347 (2018).
   PubMed Web of Science ®Google Scholar
• Brandes AA , FranceschiE, PaccapeloAet al. Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma: clinical implications. Oncologist22(4), 432–437 (2017).
   PubMed Web of Science ®Google Scholar
• Khan I , WaqasM, ShamimMS. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme. J. Pak. Med. Assoc.67(5), 816–817 (2017).
   PubMed Web of Science ®Google Scholar
• Bady P , KurscheidS, DelorenziMet al. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathol.135(4), 601–615 (2018).
   PubMed Web of Science ®Google Scholar
• de Groot J , Penas-PradoM, Alfaro-MunozKDet al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. pii:noz185 (2019).
   Web of Science ®Google Scholar
• Pombo Antunes AR , ScheyltjensI, DuerinckJet al. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife9, pii: e52176 (2020).
   Web of Science ®Google Scholar
• Hsu SPC , ChenYC, ChiangHCet al. Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors. J. Neurooncol.146(3), 417–426 (2020).
   PubMed Web of Science ®Google Scholar
• Duan S , YuanG, LiuXet al. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat. Commun.6, 10068 (2015).
   PubMed Web of Science ®Google Scholar
• Zhao J , ChenAX, GartrellRDet al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat. Med.25(3), 462–469 (2019).
   PubMed Web of Science ®Google Scholar